National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management
On January 9 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO d...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-03-01
|
| Series: | Infectious Disease Reports |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/idr/article/view/8543 |
| _version_ | 1818882385556537344 |
|---|---|
| author | E. Nicastri N. Petrosillo L. Lepore A. Mondi T. Ascoli Marchetti D’Offizi G. F. Palmieri L. Marchioni S. Murachelli G. Ippolito A. Antinori INMI COVID-19 Treatment Group (ICOTREG) |
| author_facet | E. Nicastri N. Petrosillo L. Lepore A. Mondi T. Ascoli Marchetti D’Offizi G. F. Palmieri L. Marchioni S. Murachelli G. Ippolito A. Antinori INMI COVID-19 Treatment Group (ICOTREG) |
| author_sort | E. Nicastri |
| collection | DOAJ |
| description | On January 9 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data. |
| first_indexed | 2024-12-19T15:16:55Z |
| format | Article |
| id | doaj.art-bff0a311c887454a8acccf0e969af955 |
| institution | Directory Open Access Journal |
| issn | 2036-7430 2036-7449 |
| language | English |
| last_indexed | 2024-12-19T15:16:55Z |
| publishDate | 2020-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Infectious Disease Reports |
| spelling | doaj.art-bff0a311c887454a8acccf0e969af9552022-12-21T20:16:07ZengMDPI AGInfectious Disease Reports2036-74302036-74492020-03-0112110.4081/idr.2020.8543National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical ManagementE. Nicastri0N. Petrosillo1L. Lepore2A. Mondi3T. Ascoli Marchetti4D’Offizi G.5F. Palmieri6L. Marchioni7S. Murachelli8G. Ippolito9A. Antinori10INMI COVID-19 Treatment Group (ICOTREG)11National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeNational Institute for Infectious Diseases “L. Spallanzani”, IRCCS, RomeOn January 9 2020, the “World Health Organization” (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a diseases (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The “L. Spallanzani” National Institute for the Infectious Diseases, IRCCS has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; these recomendations should be considered as expert opinions, which may be modified according to newly produced literature data.https://www.pagepress.org/journals/index.php/idr/article/view/8543COVID-19SARS-CoV-2Treatment |
| spellingShingle | E. Nicastri N. Petrosillo L. Lepore A. Mondi T. Ascoli Marchetti D’Offizi G. F. Palmieri L. Marchioni S. Murachelli G. Ippolito A. Antinori INMI COVID-19 Treatment Group (ICOTREG) National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management Infectious Disease Reports COVID-19 SARS-CoV-2 Treatment |
| title | National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management |
| title_full | National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management |
| title_fullStr | National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management |
| title_full_unstemmed | National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management |
| title_short | National Institute for the Infectious Diseases “L. Spallanzani”, IRCCS. Recommendations for COVID-19 Clinical Management |
| title_sort | national institute for the infectious diseases l spallanzani irccs recommendations for covid 19 clinical management |
| topic | COVID-19 SARS-CoV-2 Treatment |
| url | https://www.pagepress.org/journals/index.php/idr/article/view/8543 |
| work_keys_str_mv | AT enicastri nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT npetrosillo nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT llepore nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT amondi nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT tascolimarchetti nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT doffizig nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT fpalmieri nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT lmarchioni nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT smurachelli nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT gippolito nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT aantinori nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement AT inmicovid19treatmentgroupicotreg nationalinstitutefortheinfectiousdiseaseslspallanzaniirccsrecommendationsforcovid19clinicalmanagement |